Literature DB >> 26960559

Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab.

R Montal1, M Oliva2, M Taberna2,3, L De Avila4, A Rovira5, M Cos6, M Mañós3,5, V Navarro7, J Nogués5, A Lozano8, L Rodríguez9, E Vilajosana2, S Vázquez2, R Mesia2,3.   

Abstract

PURPOSE: Management of residual neck disease (RND) is one of the unsolved points after bio-radiotherapy (BRT) in loco-regional advanced squamous-cell carcinoma of the head and neck (SCCHN). The aims of the study were to characterize the radiological pattern of response by computed tomography (CT) and to assess the role of positron-emission tomography (PET)/CT in this setting for a better decision-making in the indication of neck dissection (ND).
METHODS: We retrospectively reviewed 202 patients consecutively diagnosed with node-positive SCCHN (N1: 24; N2: 152; N3: 26) who had been treated with concomitant radiotherapy and cetuximab with or without previous induction chemotherapy between 2006 and 2013. Radiological evaluation after treatment was assessed by standard criteria using CT and in addition by PET/CT when RND was suspected in cases from 2010.
RESULTS: There were 42 (21 %) patients who achieved complete response of the primary tumor persisting RND by CT. From this group, 24 patients were managed without PET/CT, leading to the performance of ND in 22 (92 %). On the other hand, 18 patients underwent PET/CT and ND was performed in only 6 (33 %). The overall survival was not different between both groups (p = 0.32). After histological examination and follow-up, PET/CT obtained a positive predictive value of 56 % and a negative predictive value of 89 %.
CONCLUSIONS: Radiological response after BRT is similar to that after treatment with chemo-radiotherapy, thereby validating in this scenario the accepted CT criteria to define complete response of the neck. However, when RND is suspected by CT, PET/CT is useful to prevent unnecessary ND.

Entities:  

Keywords:  Bio-radiotherapy; Cetuximab; Neck dissection; PET/CT; Residual neck disease; Squamous-cell carcinoma of the head and neck

Mesh:

Substances:

Year:  2016        PMID: 26960559     DOI: 10.1007/s12094-016-1496-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  24 in total

1.  Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy.

Authors:  Sandro V Porceddu; David I Pryor; Elizabeth Burmeister; Bryan H Burmeister; Michael G Poulsen; Matthew C Foote; Benedict Panizza; Scott Coman; David McFarlane; William Coman
Journal:  Head Neck       Date:  2011-01-14       Impact factor: 3.147

2.  Neck dissection after chemoradiotherapy: timing and complications.

Authors:  Laura A Goguen; Claudia I Chapuy; Yi Li; Sihai D Zhao; Donald J Annino
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-11

3.  Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?

Authors:  Ronan Abgral; Solène Querellou; Gaël Potard; Pierre-Yves Le Roux; Alexandra Le Duc-Pennec; Remi Marianovski; Olivier Pradier; Yves Bizais; Françoise Kraeber-Bodéré; Pierre Y Salaun
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

4.  The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.

Authors:  Sébastien Clavel; Marie-Pierre Charron; Manon Bélair; Guila Delouya; Bernard Fortin; Philippe Després; Denis Soulières; Edith Filion; Louis Guertin; Phuc Felix Nguyen-Tan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-09       Impact factor: 7.038

5.  Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer.

Authors:  Anuj Goenka; Luc G T Morris; Shyam S Rao; Suzanne L Wolden; Richard J Wong; Dennis H Kraus; Nisha Ohri; Jeremy Setton; Benjamin H Lok; Nadeem Riaz; Borys R Mychalczak; Heiko Schoder; Ian Ganly; Jatin P Shah; David G Pfister; Michael J Zelefsky; Nancy Y Lee
Journal:  Int J Cancer       Date:  2013-03-29       Impact factor: 7.396

6.  Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease?

Authors:  Maria Cristina Da Mosto; Valentina Lupato; Salvatore Romeo; Giacomo Spinato; Giancarlo Addonisio; Vittorio Baggio; Alessandro Gava; Paolo Boscolo-Rizzo
Journal:  Ann Surg Oncol       Date:  2012-07-27       Impact factor: 5.344

7.  Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy.

Authors:  Ann Tan; David J Adelstein; Lisa A Rybicki; Jerrold P Saxton; Ramon M Esclamado; Benjamin G Wood; Robert R Lorenz; Marshall Strome; Marjorie A Carroll
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-05

Review 8.  Controversies in surgical management of the node-positive neck after chemoradiation.

Authors:  Miriam N Lango; Jeffrey N Myers; Adam S Garden
Journal:  Semin Radiat Oncol       Date:  2009-01       Impact factor: 5.934

9.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

10.  Neck control after definitive radiochemotherapy without planned neck dissection in node-positive head and neck cancers.

Authors:  Na Young Jang; Keun-Wook Lee; Soon-Hyun Ahn; Jae-Sung Kim; In Ah Kim
Journal:  BMC Cancer       Date:  2012-02-07       Impact factor: 4.430

View more
  1 in total

1.  Nobiletin inhibits cell growth through restraining aerobic glycolysis via PKA-CREB pathway in oral squamous cell carcinoma.

Authors:  Chong-Xiang Lin; Cheng-Wei Tu; Yi-Ke Ma; Peng-Cheng Ye; Xia Shao; Zhao-An Yang; Yi-Ming Fang
Journal:  Food Sci Nutr       Date:  2020-05-21       Impact factor: 2.863

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.